Regeneron's EYLEA Submitted for EU Marketing Authorization for Treatment of Macular Edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Bayer HealthCare today announced that Bayer HealthCare (OTC: BAYRY ) has submitted an application for marketing authorization in Europe for EYLEA (aflibercept) Injection for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO). "It is our pleasure to announce